Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Applied Therapeutics (APLT)
:APLT
RESEARCH TOOLSreports
APLT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.54 - $10.62
Previous CloseN/A
Volume3.84M
Average Volume (3M)4.85M
Market Cap
$65.76M
Enterprise Value$1.13B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Mar 14, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding116,356,476
10 Day Avg. Volume3,011,422
30 Day Avg. Volume4,846,104
Standard Deviation0.37
R-Squared0.07
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.70
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap17.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit117.22
Enterprise Value/Ebitda-12.26
Forecast
1Y Price Target
$4.83Price Target Upside762.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Community SupportGovorestat still has a lot of support from the galactosemia KOL community and patient advocates, highlighting the unmet need.
Leadership ChangesAPLT has announced John H. Johnson, an industry veteran with more than 40 years of experience, will serve as Executive Chairman, and Les Funtleyder, who is currently the CFO and has served on APLT's board, will serve as interim CEO.
SORD ProgramThe SORD program alone, which is independent and being reviewed by Neurology I under accelerated approval, is worth a significant value per share.
Bears Say
Market ImpactThe FDA's warning letter has significantly affected management’s reputation, likely impacting near-term investor sentiment.
Regulatory ChallengesAPLT received a CRL for govorestat in classic galactosemia, which was followed by a warning letter from the FDA.
Uncertainty In Govorestat's FutureDowngrading Shares to Market Perform Due to Increased Uncertainty Around Govorestat's Future and Limited Cash.
---
Ownership Overview
14.95% Insiders
8.56% Mutual Funds
0.27% Other Institutional Investors
59.87% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
APLT FAQ
What was Applied Therapeutics’s price range in the past 12 months?
Applied Therapeutics lowest stock price was $0.54 and its highest was $10.62 in the past 12 months.
What is Applied Therapeutics’s market cap?
Applied Therapeutics’s market cap is $65.76M.
When is Applied Therapeutics’s upcoming earnings report date?
Applied Therapeutics’s upcoming earnings report date is Mar 14, 2025 which is in 20 days.
How were Applied Therapeutics’s earnings last quarter?
Applied Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.158 by -$0.322.
Is Applied Therapeutics overvalued?
According to Wall Street analysts Applied Therapeutics’s price is currently Undervalued.
Does Applied Therapeutics pay dividends?
Applied Therapeutics does not currently pay dividends.
What is Applied Therapeutics’s EPS estimate?
Applied Therapeutics’s EPS estimate is -0.2.
How many shares outstanding does Applied Therapeutics have?
Applied Therapeutics has 116,356,476 shares outstanding.
What happened to Applied Therapeutics’s price movement after its last earnings report?
Applied Therapeutics reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.158. Following the earnings report the stock price went up 0.933%.
Which hedge fund is a major shareholder of Applied Therapeutics?
Currently, no hedge funds are holding shares in APLT
---
Applied Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.83 (762.50% Upside)
$4.83 (762.50% Upside)
Blogger Sentiment
Bullish
APLT Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $83.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.6%
Last 30 Days ▼ 7.6%
Last 30 Days ▼ 7.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-89.35%
12-Months-Change
Fundamentals
Return on Equity
-3179.06%
Trailing 12-Months
Asset Growth
135.79%
Trailing 12-Months
Company Description
Applied Therapeutics
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.
---
APLT Stock 12 Month Forecast
Average Price Target
$4.83
▲(762.50% Upside)
Technical Analysis
Xoma
―
RedHill Biopharma
―
Ocular Therapeutix
―
Protagonist Therapeutics
―
Annovis Bio
―
Best Analysts Covering APLT
1 Year
1 Year Success Rate
11/32 ratings generated profit
1 Year Average Return
+56.14%
reiterated a buy rating 3 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 34.38% of your transactions generating a profit, with an average return of +56.14% per trade.
---